Going deeper into the new world of genetic medicine, the FDA has for the second time approved a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. And more could be on the way.
The drug is larotrectinib (Vitrakvi), from Loxo Oncology (NASDAQ: LOXO), and it has been designed to knock out tumors in which a gene called NTRK has abnormally fused to another gene. The abnormality occurs in up to 1 percent of all solid tumor types, including cancers of the kidney, bladder, stomach, and lung.
The FDA has approved… Read more »
UNDERWRITERS AND PARTNERS